FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma

On July 31, 2009, the U.S. Food and Drug Administration granted approval for the use of bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA) in combination with interferon (IFN)-α2a for the treatment of patients with metastatic renal cell carcinoma. The approval was primarily based on re...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Summers, Jeff, Cohen, Martin H., Keegan, Patricia, Pazdur, Richard
Format: Artigo
Sprog:Inglês
Udgivet: AlphaMed Press 2010
Fag:
Regulatory Issues: FDA
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227879/
https://ncbi.nlm.nih.gov/pubmed/20061402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0250
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker